Davis Polk advised J.P. Morgan Securities LLC, Merrill Lynch, Pierce Fenner & Smith Incorporated and Morgan Stanley & Co. LLC as joint book-running managers on an SEC-registered offering by Celgene Corporation of $500 million aggregate principal amount of its 1.9% senior notes due 2017 and $1 billion aggregate principal amount of its 3.25% senior notes due 2022.
Headquartered in Summit, New Jersey, Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory-related diseases.
The Davis Polk corporate team included partner Richard D. Truesdell Jr. and associates Jonathan C. Pentzien, Sarah Ashfaq and Marcus Hintze. Associate David R. Bauer provided intellectual property advice. Partner Neil Barr provided tax advice. Kristyn M. Dunleavy was the legal assistant on the transaction. All members of the Davis Polk team are based in the New York.
